Answers are grounded in this paper and cite their sources.
Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer. Olaparib inhibits poly(ADP-ribose) polymerase, thereby blocking the repair of single-strand DNA breaks. This results in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination.
No takes yet. Share an insight, caveat, or question.
Goulooze et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: